港股異動丨信達生物反彈超14% 放棄售國際業務股權予創始人
此前持續走弱的信達生物(1801.HK)今日大幅反彈,盤初一度升14.27%報40.05港元。該公司一個多星期後放棄售國際業務Fortvita股權予創始人持有的Lostrancos。信達生物10月25日公佈,Lostrancos計劃認購信達旗下Fortvita 2050萬美元優先股,交易完成後,信達生物於Fortvita持股由100%被攤薄至79.61%,Lostrancos則持有餘下20.39%的Fortvita股權。信達生物昨晚表示,Fortvita與Lostrancos經進一步考慮後,雙方同意透過Fortvita與Lostrancos昨日訂立的終止協議,以終止該認購協議。公司重申其對發展國際業務的積極願景,及Fortvita作為開展海外業務的平台,在推動公司成為全球性生物製藥企業的長期目標方面的作用。建議認購事項旨在表明管理層對發展公司國際業務的長期承諾。然而,自上月25日宣佈建議認購事項以來,公司收到其股東對該提案的反饋及不同看法。公司與董事會已審慎考慮,並決定不繼續進行建議認購事項。因此,Fortvita和Lostrancos已共同同意終止認購協議。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.